(Q39650689)

English

Phase II evaluation of LY2603618, a first-generation CHK1 inhibitor, in combination with pemetrexed in patients with advanced or metastatic non-small cell lung cancer.

scientific article published on 27 June 2016

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27350064%20AND%20SRC:MED&resulttype=core&format=json

16 March 2020

Phase II evaluation of LY2603618, a first-generation CHK1 inhibitor, in combination with pemetrexed in patients with advanced or metastatic non-small cell lung cancer (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27350064%20AND%20SRC:MED&resulttype=core&format=json

16 March 2020

Giorgio Scagliotti

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27350064%20AND%20SRC:MED&resulttype=core&format=json

16 March 2020

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27350064%20AND%20SRC:MED&resulttype=core&format=json

16 March 2020

author name string

Jin Hyoung Kang

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27350064%20AND%20SRC:MED&resulttype=core&format=json

16 March 2020

David Smith

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27350064%20AND%20SRC:MED&resulttype=core&format=json

16 March 2020

Richard Rosenberg

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27350064%20AND%20SRC:MED&resulttype=core&format=json

16 March 2020

Keunchil Park

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27350064%20AND%20SRC:MED&resulttype=core&format=json

16 March 2020

Sang-We Kim

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27350064%20AND%20SRC:MED&resulttype=core&format=json

16 March 2020

Thomas E Boyd

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27350064%20AND%20SRC:MED&resulttype=core&format=json

16 March 2020

Donald A Richards

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27350064%20AND%20SRC:MED&resulttype=core&format=json

16 March 2020

Silvia Novello

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27350064%20AND%20SRC:MED&resulttype=core&format=json

16 March 2020

Scott M Hynes

11

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27350064%20AND%20SRC:MED&resulttype=core&format=json

16 March 2020

Scott P Myrand

12

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27350064%20AND%20SRC:MED&resulttype=core&format=json

16 March 2020

Ji Lin

13

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27350064%20AND%20SRC:MED&resulttype=core&format=json

16 March 2020

Emily Nash Smyth

14

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27350064%20AND%20SRC:MED&resulttype=core&format=json

16 March 2020

Sameera Wijayawardana

15

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27350064%20AND%20SRC:MED&resulttype=core&format=json

16 March 2020

Aimee Bence Lin

16

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27350064%20AND%20SRC:MED&resulttype=core&format=json

16 March 2020

Mary Pinder-Schenck

17

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27350064%20AND%20SRC:MED&resulttype=core&format=json

16 March 2020

language of work or name

1 reference

based on heuristic

inferred from title

publication date

27 June 2016

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27350064%20AND%20SRC:MED&resulttype=core&format=json

16 March 2020

Investigational New Drugs

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27350064%20AND%20SRC:MED&resulttype=core&format=json

16 March 2020

34

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27350064%20AND%20SRC:MED&resulttype=core&format=json

16 March 2020

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27350064%20AND%20SRC:MED&resulttype=core&format=json

16 March 2020

625-635

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27350064%20AND%20SRC:MED&resulttype=core&format=json

16 March 2020

Cancer statistics, 2014

1 reference

https://api.crossref.org/works/10.1007%2FS10637-016-0368-1

21 January 2018

Management of non-small-cell lung cancer: recent developments

1 reference

https://api.crossref.org/works/10.1007%2FS10637-016-0368-1

21 January 2018

Conservation of the Chk1 checkpoint pathway in mammals: linkage of DNA damage to Cdk regulation through Cdc25

1 reference

https://api.crossref.org/works/10.1007%2FS10637-016-0368-1

21 January 2018

Preclinical analyses and phase I evaluation of LY2603618 administered in combination with pemetrexed and cisplatin in patients with advanced cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10637-016-0368-1

21 January 2018

Phase I dose-escalation study to examine the safety and tolerability of LY2603618, a checkpoint 1 kinase inhibitor, administered 1 day after pemetrexed 500 mg/m(2) every 21 days in patients with cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10637-016-0368-1

21 January 2018

p53 down-regulates CHK1 through p21 and the retinoblastoma protein

1 reference

https://api.crossref.org/works/10.1007%2FS10637-016-0368-1

21 January 2018

Comprehensive molecular profiling of lung adenocarcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS10637-016-0368-1

21 January 2018

New insights into checkpoint kinase 1 in the DNA damage response signaling network

1 reference

https://api.crossref.org/works/10.1007%2FS10637-016-0368-1

21 January 2018

CHEK again: revisiting the development of CHK1 inhibitors for cancer therapy

1 reference

https://api.crossref.org/works/10.1007%2FS10637-016-0368-1

21 January 2018

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

1 reference

https://api.crossref.org/works/10.1007%2FS10637-016-0368-1

21 January 2018

Toxicity and response criteria of the Eastern Cooperative Oncology Group

1 reference

https://api.crossref.org/works/10.1007%2FS10637-016-0368-1

21 January 2018

Identifying the target NSCLC patient for maintenance therapy: an analysis from a placebo-controlled, phase III trial of maintenance pemetrexed (H3E-MC-JMEN).

1 reference

https://api.crossref.org/works/10.1007%2FS10637-016-0368-1

21 January 2018

Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy

1 reference

https://api.crossref.org/works/10.1007%2FS10637-016-0368-1

21 January 2018

The differential efficacy of pemetrexed according to NSCLC histology: a review of two Phase III studies

1 reference

https://api.crossref.org/works/10.1007%2FS10637-016-0368-1

21 January 2018

Characterization and preclinical development of LY2603618: a selective and potent Chk1 inhibitor

1 reference

https://api.crossref.org/works/10.1007%2FS10637-016-0368-1

21 January 2018

Phase I dose-escalation trial of checkpoint kinase 1 inhibitor MK-8776 as monotherapy and in combination with gemcitabine in patients with advanced solid tumors.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-016-0368-1

21 January 2018

Phase I dose-escalation study of AZD7762, a checkpoint kinase inhibitor, in combination with gemcitabine in US patients with advanced solid tumors

1 reference

https://api.crossref.org/works/10.1007%2FS10637-016-0368-1

21 January 2018

Phase I, dose-escalation study of AZD7762 alone and in combination with gemcitabine in Japanese patients with advanced solid tumours

1 reference

https://api.crossref.org/works/10.1007%2FS10637-016-0368-1

21 January 2018

Analysis of EGFR, KRAS and P53 mutations in lung cancer using cells in the curette lavage fluid obtained by bronchoscopy.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-016-0368-1

21 January 2018

Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database

1 reference

https://api.crossref.org/works/10.1007%2FS10637-016-0368-1

21 January 2018

The p53 network in lung carcinogenesis.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-016-0368-1

21 January 2018

Wild-type p53 overexpression and its correlation with MDM2 and p14ARF alterations: an alternative pathway to non-small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-016-0368-1

21 January 2018

Prognostic role of p53 in stage III non-small cell lung cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/27350064

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I Study of GDC-0425, a Checkpoint Kinase 1 Inhibitor, in Combination with Gemcitabine in Patients with Refractory Solid Tumors

1 reference

https://pubmed.ncbi.nlm.nih.gov/27350064

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S10637-016-0368-1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27350064%20AND%20SRC:MED&resulttype=core&format=json

16 March 2020

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27350064%20AND%20SRC:MED&resulttype=core&format=json

16 March 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39650689&oldid=2203056809"